الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 80 |  |  |
| | | from | 80 | | |
Abstract
Rheumatic valve disease is still prevalent. Management of Rheumatic valve disease depends on symptomatology, physical examination and echocardiographic evaluation, all of which, however, might be inadequate.
Reliable biomarkers to establish severity of Rheumatic valve disease and predict complications would be highly beneficial.
Human urotensin II is regarded as a cardiovascular autacoid/hormone has several cardiovascular actions, including potent vasoactive, and cardiac inotropic and hypertropic properties. Urotensin II has pleiotropic effects within the cardiovascular system, with evidence for modulation of cardiac contractility, vascular tone, cell proliferation, and cell growth.
This study was conducted on 25 patients with rheumatic aortic regurgitation and another 20 age and sex matched healthy control group. The aim of this study was to measure plasma urotensin II concentrations in patients with and without chronic Rheumatic aortic regurgitation and to examine its correlation with severity of valve impairment.
Our results indicate that urotensin II level may have a diagnostic and prognostic role in the pathophysiology of rheumatic heart disease and myocardial damage associated with valvular affection. Urotensin II was found to be elevated in patients with rheumatic aortic regurgitation positively correlated with left ventricular end diastolic dimension and left ventricular end systolic dimension. Left ventricular end diastolic dimension and left ventricular end systolic dimension were found to have a strong prediction for elevated level of urotensin II.